Bharat Parenterals Ltd
BPLPHARMABharat Parenterals Ltd
BPLPHARMA
Price Chart
Scorecard
Performance
AvgPrice return has been average, nothing exciting
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
AvgAverage profitability - not good, not bad
Entry point
AvgThe stock is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| -394.43 | 4.55 | 0.05% |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 51.72 | 6.72 | 0.52% |
Forecast & Ratings
Detailed Forecast Price
Price Upside
Earnings
Earnings Growth
Revenue
Rev. Growth
Company Profile
Bharat Parenterals Limited is a pharmaceutical company that makes pharmaceutical formulations. Its products include general, beta-lactam, cephalosporins, antiretroviral, and veterinary.
Peers
Compare with peersSun Pharmaceutical Industries Ltd
Cipla Ltd
Mankind Pharma Ltd
Dr Reddy's Laboratories Ltd
Torrent Pharmaceuticals Ltd
Get more out of Tickertape, Go Pro!
Customise key metrics, see detailed forecasts, download stock data and more
Forecasts
Price
Revenue
Earnings
Price Forecast
Hmm, looks like data is unavailable here. Please come back after some timeRevenue Forecast
Hmm, looks like data is unavailable here. Please come back after some timeEarnings Per Share Forecast
Hmm, looks like data is unavailable here. Please come back after some timeIncome
Balance Sheet
Cash Flow
Income Statement
| Financial Year | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | TTM | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 128.82 | 119.11 | 143.69 | 232.24 | 239.66 | 213.31 | 219.79 | 229.72 | 265.95 | 302.43 | ||||||||||
Raw Materials | 83.88 | 80.50 | 88.81 | 142.09 | 151.88 | 132.47 | 134.39 | 147.23 | 173.54 | 287.34 | ||||||||||
| Power & Fuel Cost | 1.87 | 1.79 | 2.62 | 2.70 | 3.19 | 3.10 | 3.21 | 3.75 | 4.69 | |||||||||||
| Employee Cost | 9.10 | 11.37 | 12.94 | 15.37 | 15.58 | 14.75 | 15.37 | 18.00 | 22.78 | |||||||||||
| Selling & Administrative Expenses | 13.69 | 6.40 | 12.36 | 21.64 | 21.65 | 14.04 | 13.87 | 23.67 | 28.80 | |||||||||||
| Operating & Other expenses | 5.25 | 4.88 | 7.65 | 8.86 | 7.81 | 15.04 | 17.11 | 5.04 | 4.33 | |||||||||||
EBITDA | 15.03 | 14.17 | 19.31 | 41.58 | 39.55 | 33.91 | 35.84 | 32.03 | 31.81 | 15.09 | ||||||||||
| Depreciation/Amortization | 4.20 | 5.79 | 5.57 | 6.13 | 5.88 | 6.03 | 6.66 | 5.88 | 9.02 | 23.73 | ||||||||||
| PBIT | 10.83 | 8.38 | 13.74 | 35.45 | 33.67 | 27.88 | 29.18 | 26.15 | 22.79 | -8.64 | ||||||||||
| Interest & Other Items | 1.49 | 0.91 | 0.94 | 0.87 | 0.86 | 0.77 | 1.31 | 2.60 | 4.07 | 7.39 | ||||||||||
| PBT | 9.34 | 7.47 | 12.80 | 34.58 | 32.81 | 27.11 | 27.87 | 23.55 | 18.72 | -16.03 | ||||||||||
| Taxes & Other Items | 2.89 | 0.59 | 3.68 | 13.35 | 8.65 | 6.74 | 6.83 | 7.10 | 4.21 | -13.28 | ||||||||||
| Net Income | 6.45 | 6.88 | 9.12 | 21.23 | 24.16 | 20.37 | 21.04 | 16.45 | 14.51 | -2.75 | ||||||||||
| EPS | 11.26 | 12.01 | 15.92 | 37.05 | 42.17 | 35.55 | 36.58 | 28.49 | 25.03 | -4.73 | ||||||||||
| DPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.75 | 1.00 | 1.00 | ||||||||||
| Payout ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.03 | 0.04 | -0.21 |
Company Updates
Annual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFPeers & Comparison
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Bharat Parenterals Ltd | 74.75 | 4.55 | 0.05% |
| Sun Pharmaceutical Industries Ltd | 46.63 | 6.65 | 0.73% |
| Cipla Ltd | 29.52 | 4.54 | 0.86% |
| Mankind Pharma Ltd | 61.94 | 12.37 | — |
Price Comparison
Compare BPLPHARMA with any stock or ETFShareholdings
Promoter Holdings Trend
Low Pledged Promoter Holding
Pledged promoter holdings is insignificant
Institutional Holdings Trend
No institutional holdings trend are available
Shareholding Pattern
Mar 2024
Jun 2024
Sep 2024
Oct 2024
Shareholding History
Hmm, looks like there hasn't been any net deal activity in the last 6 monthssmallcases
Looks like this stock is not in any smallcase yet.
Events
Dividend Trend
No dividend trend available
Dividends
Corp. Actions
Announcements
Legal Orders
Upcoming Dividends
No upcoming dividends are available
Past Dividends
Cash Dividend
Ex DateEx DateJun 25, 2024
Dividend/Share
₹1.00
Ex DateEx Date
Jun 25, 2024
Cash Dividend
Ex DateEx DateSep 25, 2023
Dividend/Share
₹0.75
Ex DateEx Date
Sep 25, 2023
Net loss of Bharat Parenterals reported to Rs 7.51 crore in the quarter ended September 2024 as against net profit of Rs 3.52 crore during the previous quarter ended September 2023. Sales rose 19.76% to Rs 71.63 crore in the quarter ended September 2024 as against Rs 59.81 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales71.6359.81 20 OPM %-10.697.22 - PBDT-6.366.29 PL PBT-15.374.54 PL NP-7.513.52 PL Powered by Capital Market - Live
Bharat Parenterals will hold a meeting of the Board of Directors of the Company on 29 October 2024.Powered by Capital Market - Live
Net profit of Bharat Parenterals declined 82.98% to Rs 1.28 crore in the quarter ended June 2024 as against Rs 7.52 crore during the previous quarter ended June 2023. Sales rose 32.33% to Rs 92.51 crore in the quarter ended June 2024 as against Rs 69.91 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales92.5169.91 32 OPM %4.8514.95 - PBDT4.2611.66 -63 PBT-4.7710.08 PL NP1.287.52 -83 Powered by Capital Market - Live
Bharat Parenterals will hold a meeting of the Board of Directors of the Company on 8 August 2024Powered by Capital Market - Live
Bharat Parenterals shares surge on Q1 results
Bharat Parenterals consolidated net profit rises 113.76% in the March 2022 quarter
Bharat Parenterals consolidated net profit rises 23.26% in the September 2021 quarter
Bharat Parenterals standalone net profit rises 24.34% in the September 2021 quarter
Bharat Parenterals consolidated net profit rises 16.42% in the June 2021 quarter
Bharat Parenterals consolidated net profit declines 73.49% in the March 2021 quarter
Lower than Industry Revenue Growth
Over the last 5 years, revenue has grown at a yearly rate of 2.75%, vs industry avg of 9.04%
Decreasing Market Share
Over the last 5 years, market share decreased from 0.11% to 0.07%
Lower than Industry Net Income
Over the last 5 years, net income has grown at a yearly rate of -7.33%, vs industry avg of 15.28%